---

Controls on Legal Highs

I thought I had already explained the position. I am sorry if I have not made it clear. The emphasis behind the policy is about ensuring that we stop the supply, importation and sale of the drugs and about ensuring that we can act quickly to deal with some of the challenges that I know the shadow Minister faced in Government over mephedrone. Perhaps I share his frustration at being told by the ACMD that there was a problematic psychoactive substance and feeling that one is unable to respond. There are certainly issues; he highlighted importation issues and the general licence that could be invoked, but that does not tackle domestic supply. To ensure that drugs do not get on to the streets and into the hands of young people, it is important to deal with the problem at the border and in this country. That is why we believe that the temporary ban approach is the right way forward when a newly emerging psychoactive substance that has been indentified as harmful comes through. I would like to address the issue of whether a newly emerging substance has other uses. It is fair to make that point, and the Government will seek parallel advice from the Department for Business, Innovation and Skills on a drug's legitimate use and will develop any required impact assessment, which will inform the decision on whether to impose a temporary ban on that drug. In the event that a legitimate commercial use is identified in discussions with BIS, the Home Office will take reasonable steps in light of the ACMD's advice on the risk to public health when a substance is misused, to ensure its continued availability for legitimate use under the temporary ban and, subject to further consideration, under circumstances in which that ban is made permanent. There are examples showing how that approach could be taken. It is important to recognise that point, and advice will be sought from the Department for Business, Innovation and Skills and the ACMD in relation to the application of those powers. My hon. Friend the Member for Enfield, Southgate (Mr Burrowes) raised the issue of what other countries are doing, and gave the specific example of Ireland. I am aware of the changes that are taking place there and of the fact that the Irish are considering a broader definition of drugs. We can look, too, at the example of the United States and the analogue legislation that is in operation there. The Advisory Council on the Misuse of Drugs is considering the broad policy issues and the various different examples. Although I cannot comment on whether it is looking at the Irish situation, it is doing broader work on legal highs. We await its report on appropriate approaches, which may take into account factors such as a broader definition. I do not want to prejudge or pre-empt the work of the ACMD, but we appreciate the work that it is doing, and look forward to its response. Certainly, we are considering a proportionate response based on the tenets of harm before imposing criminal penalties. The hon. Member for Tynemouth asked whether other EU countries had taken different approaches on temporary bans. The experience is that those countries have tended to take a very narrow perspective on the utilisation of temporary banning powers. Spice was one of the cases in point. In this country, we have sought to take a more generic approach to a class of drugs, so that we avoid the issue of tweaking and slight chemical manipulation. The temporary bans and the immediate action that were taken in some other EU countries were much more narrowly focused, so we are not comparing like with like in that regard. The approach that we hope to take is very much looking at that broader categorisation rather that at one specific drug alone, without necessarily considering the analogues that may exist alongside all of that. That is very much part and parcel of the work that we would adopt. I have a couple of things to mention in relation to the New Zealand case. I am advised that its class D is currently empty, but that could be a reflection of the fact that New Zealand has not had to respond to legal highs in the way in which the United Kingdom has. It is difficult to make cross-over judgments. Moreover, the class D model envisages a regulated supply as well, which is not the approach that the UK seeks to adopt. The hon. Member for Carshalton and Wallington highlighted the issue of khat. The Government acknowledge the concern in communities affected by khat use, particularly in relation to the social problems, which include unemployment, family breakdown and financial hardship. We are committed to addressing any form of substance misuse and will keep the issue under close scrutiny. Home Office research into the social harms of khat use, as well as the treatment needs of users, was commissioned last year by the previous Government, and it looked at a number of communities and areas in England and Wales. We are quality-assuring the work and will produce an independent review of the findings, as is standard practice with all Home Office research reports. We will publish those reports later this year and consider them carefully. This has been a positive and productive discussion on a sensitive issue that has impacted on far too many communities. Reflecting on conversations with parents of children who have been adversely affected by drugs and with those who have lost very close loved ones, I can say that they underline the importance that we must place on addressing the harms linked to these so-called highs. It is incumbent on us to continue to send out the message that simply because something is marketed as legal does not necessarily mean that it is legal, and above all it certainly does not mean that it is safe. Question put and agreed to.